The impact of disopyramide on exercise capacity among patients with obstructive hypertrophic cardiomyopathy: beyond left ventricular outflow tract gradient - Summary - MDSpire

The impact of disopyramide on exercise capacity among patients with obstructive hypertrophic cardiomyopathy: beyond left ventricular outflow tract gradient

  • By

  • Geza Halasz

  • Lorenzo Lupo Dei

  • Francesco Moroni

  • Michael P Ayers

  • Paolo Ciacci

  • Guido Giacalone

  • Raffaella Mistrulli

  • Marco Redivo

  • Santiago Orellana

  • Domenico Gabrielli

  • Massimo Piepoli

  • Federica Re

  • June 8, 2024

  • 0 min

Share

Objective:

To examine the effects of disopyramide on exercise capacity and dynamic left ventricular gradient in patients with obstructive hypertrophic cardiomyopathy (oHCM), highlighting its significance in treatment options.

Key Findings:
  • Resting LVOT gradient decreased from 40 to 29 mmHg (P = 0.08), indicating a trend towards improved hemodynamics.
  • Peak exercise gradient decreased from 63 to 41 mmHg (P = 0.014), suggesting significant clinical relevance.
  • Significant reduction in resting heart rate (78 to 68 b.p.m.; P = 0.02) and peak heart rate (131 to 113 b.p.m.; P = 0.001), which may impact patient management.
  • Functional capacity decreased significantly (20 mL/kg/min to 17 mL/kg/min; P = 0.02), raising concerns about treatment effects.
  • Trends towards improved QoL (MLHFQ score reduction from 28.9 to 27; P = 0.19) and NYHA class improvement, warranting further investigation.
Interpretation:

Disopyramide effectively reduces LVOTO and may marginally improve QoL in oHCM patients, but it does not enhance exercise capacity as measured by pVO2, which has implications for treatment strategies.

Limitations:
  • Small sample size of 21 patients, which may limit generalizability.
  • Lack of control group for comparison, affecting the robustness of conclusions.
  • Short duration of follow-up (3 months), necessitating longer-term studies.
Conclusion:

Disopyramide improves symptoms and decreases LVOTO in oHCM patients but does not enhance exercise capacity or pVO2, underscoring the need for careful consideration of treatment options.

Original Source(s)

Related Content